AWM
ALNY icon

Avitas Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Avitas Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,065
Closed -$204K – 205
2023
Q4 		$204K Buy
+1,065
New +$181K 0.03% 197

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Avitas Wealth Management's ALNY Position: Q1 2024 in Review

Avitas Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 1,065 shares — an estimated $204K sold.

Avitas Wealth Management first reported a position in ALNY in Q4 2023 and held it in 1 quarter. The position peaked at $204K in Q4 2023. 499 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Avitas Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Avitas Wealth Management sold 1,065 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $204K.
  • Avitas Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Avitas Wealth Management's Alnylam Pharmaceuticals position peaked at $204K in Q4 2023.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Avitas Wealth Management's 13F filing for Q1 2024, filed 24 Apr 2024.